Introduction
After cerebral ischemia, the highly complex pathophysiological process that follows can be separated into 3 successive phases: metabolic stress and excitotoxicity (acute, within hours), inflammation and apoptosis (subacute, hours to days), and repair and regeneration (chronic, days to months) [1, 2] . Post-ischemic inflammation in the subacute phase is an important event in which a large number of cells and molecules/mediators are involved. Among the inflammatory cells, the accumulation of neutrophils and macrophage/microglia in the brain is a determinant in pathogenesis [3] [4] [5] . Cysteinyl leukotrienes (CysLT, including LTC 4 , LTD 4 and LTE 4 ), the 5-lipoxygenase metabolites of arachidonic acid, represent one type of pro-inflammatory mediator involved in cerebral ischemia [6] [7] [8] [9] . CysLT can increase blood-brain barrier (BBB) permeability and induce brain edema after cerebral ischemia and neutrophil perfusion [6, 9] . However, their actions on inflammatory cells in the ischemic brain are still unknown, although neutrophil-endothelial cell cooperation has been suggested to induce brain edema via production of CysLT in guinea pig brains perfused with human neutrophils [9] . In peripheral tissues, CysLT can increase eosinophil adhesion [10] and transendothelial migration [11] , which are involved in airway eosinophilic inflammation in asthma [12] . The pro-inflammatory actions of CysLT are mediated by activating cysteinyl leukotriene receptors (CysLT 1 and CysLT 2 ) [13] . CysLT 1 receptor mRNA has been detected by Northern blotting in the brain [14] , and its protein is primarily expressed in microvascular endothelium in human brain tissues [15] . We previously found that the CysLT 1 receptor antagonists pranlukast (ONO-1078) and montelukast protected against acute and chronic ischemic brain injury in rats and mice [16] [17] [18] [19] [20] [21] . This effect may partly result from inhibiting BBB permeability, brain edema, and glial scar formation [17, 20, 21] . However, whether pranlukast inhibits inflammatory cells in ischemic brain tissue is not yet clear.
Therefore, to further determine whether the protective effect of pranlukast is associated with anti-inflammatory activity, in the present study we observed its effect on cerebral ischemia-induced neutrophil and macrophage/microglial accumulation as well as BBB disruption and neuronal injury in mice with focal cerebral ischemia.
Materials and methods
Materials Pranlukast (ONO-1078) was kindly provided by Dr Masami TSUBOSHIMA (Ono Pharmaceutical Co, Osaka, Japan). Chloral hydrate, 2,3,5-triphenyltetrazolium chloride (TTC) and biotinylated anti-mouse IgG antibody were purchased from Sigma (St Louis, USA). Fluoro-Jade B was purchased from Chemicon International (Temecula, CA, USA). Biotinylated anti-rabbit IgG, biotinylated anti-rat IgG, horseradish peroxidase streptavidin and 3,3'-diaminobenzidine were purchased from Zhongshan Biotechnology (Beijing, China). Polyclonal rabbit anti-myeloperoxidase (MPO) and monoclonal rat anti-CD11b antibodies were purchased from Serotec (Oxford, UK).
Physiological parameter monitoring Male Kunming mice weighing 25-30 g (Shanghai Experimental Animal Center, China; Certificate No 22-001004) were used in this study. Mice were housed in a controlled temperature environment, with a 12 h light/12 h dark cycle, and allowed free access to food and water. All experiments were carried out in accordance with the National Institute of Health's Guide for the Care and Use of Laboratory Animals.
Mice were anesthetized by intraperitoneal injection of chloral hydrate (400 mg/kg). A polyethylene tube was inserted into the right femoral artery for continuously monitoring blood pressure, by using a computer-assisted system (MedLab-U/4cs; Nanjing MedEase, Nanjing, China), and for measuring P aO2 , P aCO2 , and arterial blood pH (ABL 330 blood gas analyzer; Leidu, Denmark). Blood glucose was monitored by using a one touch basic blood glucose monitoring system (Lifescan, USA). Rectal (core) temperature was measured and maintained at 37.0±0.5 ºC with a heating pad and a heating lamp during the surgery.
Focal cerebral ischemia Focal cerebral ischemia was induced by permanent middle cerebral artery occlusion (MCAO) as previously described [20] . Briefly, a 6-0 nylon monofilament suture, blunted at the tip and coated with 1% poly-L-lysine, was inserted into the right internal carotid artery, and advanced approximately 10 mm distal to the carotid bifurcation to occlude the origin of the middle cerebral artery. In sham-operated animals, the same procedure was carried out, except that an intraluminal filament was inserted. Pranlukast (0.01 and 0.1 mg/kg) was ip injected 30 min before and 30 min after MCAO.
Neurological deficits and histopathological assessment Neurological deficit scores were evaluated 72 h after MCAO as described by Bederson et al [22] : 0, no deficit; 1, failure to extend left forepaw fully; 2, circling to the left; 3, failing to the left; 4, no spontaneous walking with a depressed level of consciousness.
Mice were re-anesthetized 72 h after MCAO, and brains were quickly removed and dissected into 1.5 mm-thick coronal slices. The slices were stained with 0.5% TTC at 37 o C for 30 min, and then fixed in a 10% buffered formalin solution. The stained slices with the caudal face upward were photographed by a charge coupling device CCD camera (CP 230; Panasonic, Japan) and images were recorded on a computer. Adjusted infarct area and both hemisphere areas of each slice were determined by using an image analysis program (AnalyPower 1.0; Zhejiang University, Hangzhou, China) as reported elsewhere [20] . Infarct volume was calculated as lesion area×thickness (1.5 mm). The summation of the infarct volumes of all brain slices was the total infarct volume.
In another series, mice were deeply anesthetized 72 h after MCAO, and perfused transcardially with saline followed by 4% paraformaldehyde in 0.1 mol/L phosphate buffer (pH 7.4). The brains were removed, and fixed overnight in the same fixative as described earlier, and then immersed in 30% sucrose solution in phosphate buffer. The brains were frozen and 20 µm-or 10 µm-thick coronal sections were cut by cryomicrotomy (CM1900; Leica, Germany). The 10 µm-thick sections were used for immunohistochemical analysis, and the 20 µm-thick sections were stained with 0.0004% FluoroJade B to detect degenerated neurons by fluorescent microscopy [23] . Immunohistochemical analyses To determine neutrophil and macrophage/microglial accumulation, the brain sections were immunostained with anti-MPO (marker of neutrophils) [24] or anti-CD11b (marker of macrophage/ microglia) antibodies [25] . The 10 µm-thick sections were sequentially incubated with 5% goat serum for 2 h, rabbit polyclonal anti-MPO (1:200) or rat monoclonal anti-CD11b (1:200) antibodies overnight, biotinylated anti-rabbit and antirat IgG (1:200) for 2 h, and streptavidin avidin-biotin-horseradish peroxidase complex (1:200) for 2 h. Finally, the sections were exposed for 5-20 min to 0.01% 3,3'-diaminobenzidine.
Endogenous IgG immunostaining was performed to detect BBB disruption [26] . Brain sections were reacted respectively and successively with biotinylated anti-mouse IgG antibody (1:500), horseradish peroxidase streptavidin (1:200) and 3,3'-diaminobenzidine. The gray scales in the immunostained sections were detected with an image analyzer (Imagetool 2.0; University of Texas Health Science Center, San Antonio, TX, USA). IgG exudation was evaluated as the percentage increase of the gray scale in the ischemic hemisphere: (Gi-G 0 )/G 0 ×l00%, where Gi is the gray scale of the ischemic hemisphere and G 0 is the gray scale of the con-tralateral non-ischemic hemisphere.
Statistical analysis Values are presented as mean±SD. One-way ANOVA (Student-Newman-Keuls) or the nonparametric Mann-Whitney U-test was used for statistical analysis using the SPSS software package (version 10.0 for Windows; SPSS, USA). P<0.05 was considered statistically significant.
Results
There were no significant differences in mean arterial blood pressure, or arterial blood P aO2 , P aCO2 , or blood glucose between 30 min before and 30 min after MCAO among the groups treated with saline and pranlukast (0.01 and 0.1 mg/kg) as well as those animals that received a sham operation (Table 1 Figure 1 ). The number of FluoroJade B-positive cells (degenerated neurons) in the temporoparietal cortex III and IV layers was increased 72 h after MCAO, and significantly reduced by pranlukast (0.01 and 0.1 mg/kg; Figure 2 ). In addition, endogenous IgG immunoreactivity was increased by 22.2%±4.2% in the ischemic hemisphere as compared with the contralateral non-ischemic hemisphere, and pranlukast (0.01 and 0.1 mg/kg) markedly reduced IgG exudation (Figure 3) .
The numbers of MPO-positive neutrophils and CD11b-positive macrophages/microglia were increased in the ischemic boundary region 72 h after MCAO (Figures 4 and 5) . Pranlukast (0.01 and 0.1 mg/kg) significantly inhibited neutrophil accumulation ( Figure 4C, 4D ), but did not inhibit macrophage/microglial accumulation ( Figure 5C, 5D) .
Discussion
In the present study, the most important finding is that pranlukast inhibited neutrophil but not macrophage/microglial accumulation in ischemic brain tissue 72 h after MCAO in mice, in addition to ameliorating neurological deficits and neuron degeneration and reducing infarct volume and IgG exudation. These results not only further confirm the neuroprotective effect of pranlukast on focal cerebral ischemia as reported elsewhere [16] [17] [18] [19] [20] [21] , but also demonstrate its anti-inflammatory properties.
The effect of pranlukast on post-ischemic neutrophil accumulation might result from the inhibition of BBB disruption. The present results indicate that pranlukast inhibits endogenous IgG exudation, an indicator of BBB disruption, as found in previous studies through endogenous plasma albumin or Evans blue staining [16, 17, 20] . Because neutrophils are hematogenous inflammatory cells, their accumulation in ischemic brain tissues may reflect BBB disruption because the disrupted BBB has been reported to promote blood leukocyte recruitment [2, 5] . The lack of effect of pranlukast on post-ischemic macrophage/microglial accumulation might indicate that CysLT 1 receptor is not involved in this response in the subacute phase (72 h after MCAO). Resident microglia and hematogenous macrophages play similar roles in the pathogenetic cascade following cerebral ischemia, and both of them are CD11b-positive, but distinction between these cells has not been possible due to a lack of discriminating cellular markers [25, 27] . However, in mice transplanted with green fluorescent protein (GFP)-transgenic bone marrow, hematogenous GFP + macrophages were rarely observed on d 2, reached peak numbers on d 7, and decreased thereafter; in contrast, resident GFP -microglia rapidly became activated on d 1 after MCAO [27] . Therefore, most CD11b-positive cells 72 h after MCAO in the present study might be activated resident microglia. Although the activation of microglia in the subacute phase might not be regulated by CysLT 1 receptor, further observations are needed, because this receptor may be expressed in later phases, and many other factors may influence the effect of pranlukast.
In summary, pranlukast inhibits post-ischemic inflammation in the brain, mainly acting on the recruitment of hematogenous inflammatory cells (such as neutrophils) via inhibiting BBB disruption. This finding is consistent with the localization of CysLT 1 receptor in microvascular endothelium in the human brain [15] . The anti-inflammatory effects of pranlukast have been reported in peripheral tissues, for example allergen-induced interleukin-5 production in human lung tissue [28] , transendothelial migration of eosinophils across human umbilical vein endothelial cells in response to LTD 4 [11] , and eosinophil adhesion [10] . In the present paper, we demonstrated the anti-inflammatory effect of pranlukast in the focal ischemic brain, but this effect might be limited to BBB disruption-associated neutrophil recruitment. Thus, the present study indicates that the anti-inflammatory effect of pranlukast may be partly involved in its neuroprotective effect against cerebral ischemic injury.
